(Q44682727)

5 December 2017

title

Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis (English)

1 reference

5 December 2017

1 reference

Giuseppe Intini

1

1 reference

5 December 2017

Alfredo Aguirre

series ordinal

2

1 reference

5 December 2017

Libuse Anna Bobek

series ordinal

3

1 reference

5 December 2017

publication date

1 December 2003

1 reference

International Journal of Antimicrobial Agents

5 December 2017

published in

1 reference

5 December 2017

volume

22

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

594-600

1 reference

Current and future antifungal therapy: new targets for antifungal therapy

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Diagnosis and prevention of fungal infection in the immunocompromized patient

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Antimicrobial peptides in mammalian and insect host defence

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Divergent solid-phase synthesis and candidacidal activity of MUC7 D1, a 51-residue histidine-rich N-terminal domain of human salivary mucin MUC7

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

MUC7 20-Mer: investigation of antimicrobial activity, secondary structure, and possible mechanism of antifungal action

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: a phase-2 multi-center study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)1

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Control of Candida albicans murine vaginitis by topical administration of polycarbophil-econazole complex

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Efficacy of syringomycin E in a murine model of vaginal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

A murine model of Candida glabrata vaginitis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Antifungal drug susceptibility of Candida albicans.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Stability of protein formulations: investigation of surfactant effects by a novel EPR spectroscopic technique

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

1 reference

7 January 2021

Antimicrobial peptides: properties and applicability

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

Zeamatin, clotrimazole and nikkomycin Z in therapy of a Candida vaginitis model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2803%2900243-7

7 January 2021

10.1016/S0924-8579(03)00243-7

Identifiers

DOI

1 reference

5 December 2017

1 reference